✦ LIBER ✦

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

✍ Scribed by Tol, J.; Koopman, M.; Rodenburg, C. J.; Cats, A.; Creemers, G. J.; Schrama, J. G.; Erdkamp, F. L. G.; Vos, A. H.; Mol, L.; Antonini, N. F.; Punt, C. J. A.

Book ID: 126623915
Publisher: Oxford University Press
Year: 2008
Tongue: English
Weight: 76 KB
Volume: 19
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mdm607

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3000 ORAL Randomised phase III study of

3000 ORAL Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis

✍ J. Tol; M. Koopman; C.J. Rodenburg; A. Cats; G.J. Creemers; C.A.M. de Swart; F.L 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 76 KB

600 ORAL Randomised study of sequential

600 ORAL Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC), an interim safety analysis. a Dutch Colorectal Cancer Group (DCCG) phase III study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 133 KB

PD-068 An exploratory analysis of a phas

PD-068 An exploratory analysis of a phase III study in patients with advanced non-small cell lung cancer (NSCLC): The impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel

✍ Bunn, P.; Rosell, R.; Fossella, F.; Perry, M.; Stahel, R.; Barata, F.; Nguyen, B 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB